The company states: “Acadia Pharmaceuticals (ACAD) announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID ‘740 composition of matter patent. The affirmance came in Acadia’s litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA filers.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $30 from $26 at JPMorgan
- Acadia Pharmaceuticals price target raised to $23 from $18 at BofA
- Acadia Pharmaceuticals Holds 2025 Annual Stockholder Meeting
- UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
- Deutsche upgrades Acadia to Buy on new ‘valuation floor’